Adherium is a digital health company dedicated to developing technologies that address suboptimal medication use and remote patient management in chronic disease.
Read more about Adherium digital health lists on ASX at 10% premium
AmpliPhi Biosciences Corporation (OTCQB: APHBD), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements.
Australians and New Zealanders have an opportunity to invest in a highly promising digital health technology company that substantially improves medication adherence and patient health outcomes with the imminent Australian Securities Exchange (ASX) listing of Adherium Limited.
New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a one-for-fifty reverse split of the company’s common stock to become effective at market open on August 07, 2015.
20 July 2015 – Link here.
SeaDragon Limited (NZX:SEA) today releases an update to the market detailing the company’s progress towards completing the Omega-3 production plant. The update also includes an overview of...
Read more about Sea Dragon – Market Update
22 July 2015 – link here.
Read more about Avita Medical Shareholder Update
Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users, is pleased to announce that it has today signed a new agreement for a partnership in China with MAAB Group, an investment and trading company that specialises in sourcing and introducing innovative medical technologies into China.
20 July 2015. Link here.
Read more about Avita’s ReCell featured in US Army Technology Magazine